Eric Faulkner - 02 Mar 2026 Form 4 Insider Report for CNS Pharmaceuticals, Inc. (CNSP)

Role: Chief Technology Officer
Signature: /s/ Christopher Downs, Attorney-in-fact
Issuer symbol: CNSP
Transactions as of: 02 Mar 2026
Net transactions value: $0
Form type: 4
Filing time: 04 Mar 2026, 17:02:29 UTC
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Faulkner Eric	Chief Technology Officer	C/O CNS PHARMACEUTICALS, INC., 100 WEST LOOP SOUTH, SUITE 900, HOUSTON	/s/ Christopher Downs, Attorney-in-fact	04 Mar 2026	0002113815

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CNSP	Restricted Stock Units	Award		+9,500			9,500	02 Mar 2026	Common Stock	9,500		Direct	F1, F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit represents a contingent right to receive one share of Company common stock.
F2	The restricted stock units set forth in the table vest as follows: 25% on the six-month anniversary of the transaction date, 25% on the twelve-month anniversary of the transaction date, and the remaining 50% in twelve quarterly installments thereafter, subject to the reporting person's continued employment on each vesting date.
F3	Issued in connection with the reporting person's employment with the Company.